Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

The Influence of CYP2C19 Gene Polymorphism on Selective Serotonin Reuptake Inhibitors In Patients with Major Depressive Disorder: A Pharmacogenetic Prospecting Approach

Journal of Biomedicine and Translational Research · Vol. 10 No. 1 (2024) · hlm. 40–47

DOI
10.14710/jbtr.v10i1.20338
ISSN
2503-2178
Terbit
2024-04-30
Penerbit
Faculty of Medicine, Universitas Diponegoro
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-sa/4.0

Abstrak

Major Depressive Disorder (MDD) is a chronic disorder characterized by at least a two-week-long major depressive episode. Selective Serotonin Reuptake Inhibitors (SSRIs) remain the primary prescribed antidepressants to treat MDD. However, SSRIs themselves are found to be ineffective in some individuals or may even lead to adverse side effects. These variable responses have been linked to the drug being metabolized by CYP2C19, which exhibited various polymorphisms. Understanding how gene polymorphism affects drug metabolism is essential since these insights can revolutionize clinical practice, allowing for more precise and personalized treatment approaches that optimize efficacy while minimizing side effects. This issue is particularly pertinent in Indonesia, where research in this area lags behind the pressing need for such studies. In this review, the impact of CYP2C19 polymorphism on the effectiveness of SSRI class drugs, namely citalopram, escitalopram, and sertraline, are explored. Nine relevant articles related to the topic have been studied in Japan, China, Turkey, Russia, Scandinavia, and Australia. The results concluded that CYP2C19 polymorphism can influence the metabolism of SSRIs (citalopram, escitalopram, and sertraline) due to its variability in enzyme activities, which includes both loss-of-function (*2, *3) and gain-of-function (*17) polymorphisms. Consequently, these genetic variations can lead to significant changes in drug efficacy and safety changes within individual patients. This review sheds light on the importance of considering genetic factors when prescribing SSRIs for MDD in the future treatment strategies.

Kata kunci

Jaringan kolaborasi para penulis

19 penulis · 55 tautan kepenulisan bersama · 18 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • University of Singaperbangsa Karawang
  • Montana State University
  • Poznan University of Medical Sciences
  • Universitas Sumatera Utara
  • Universitas Muhammadiyah Prof Dr Hamka
  • IPB University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Seagames WaluyoAfiliasi tidak diketahui2
Edwin YulianAfiliasi tidak diketahui2
Imam HardimanUniversitas Muhammadiyah Prof Dr Hamka2
Ocha Putri MuliaUniversity of Indonesia1
Febri LS LarosaUniversity of Indonesia1
Tri Hastuti SeptiariniUniversity of Indonesia1
Herman SuryadiUniversity of Indonesia1
Muhammad Ghildan Arifudin RafifAfiliasi tidak diketahui1
Maria Indah PurnamasariMontana State University1
Antonius SuwantoIPB University1
Widyah BudinartaAfiliasi tidak diketahui1
Cahya PrihatnaMontana State University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ejournal2.undip.ac.id/index.php/jbtr/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 9 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Influence of CYP2C19 Gene Polymorphism on Selective Serotonin Reuptake Inhibitors In Patients with Major Depressive Disorder: A Pharmacogenetic Prospecting Approach</dc:title>
	<dc:creator>Urbaningrum, Lestari Mahardika</dc:creator>
	<dc:creator>Hermosaningtyas, Anastasia Aliesa</dc:creator>
	<dc:creator>Kasasiah, Ahsanal</dc:creator>
	<dc:creator>Rahmasari, Ratika</dc:creator>
	<dc:creator>Raekiansyah, Muhareva</dc:creator>
	<dc:creator>Hartanto, Adrian</dc:creator>
	<dc:creator>Malau, Jekmal</dc:creator>
	<dc:subject xml:lang="en-US">Major Depressive Disorder; CYP2C19; Gene Polymorphism; Selective Serotonin Reuptake Inhibitors; Drug Metabolism</dc:subject>
	<dc:description xml:lang="en-US">Major Depressive Disorder (MDD) is a chronic disorder characterized by at least a two-week-long major depressive episode. Selective Serotonin Reuptake Inhibitors (SSRIs) remain the primary prescribed antidepressants to treat MDD. However, SSRIs themselves are found to be ineffective in some individuals or may even lead to adverse side effects. These variable responses have been linked to the drug being metabolized by CYP2C19, which exhibited various polymorphisms. Understanding how gene polymorphism affects drug metabolism is essential since these insights can revolutionize clinical practice, allowing for more precise and personalized treatment approaches that optimize efficacy while minimizing side effects. This issue is particularly pertinent in Indonesia, where research in this area lags behind the pressing need for such studies. In this review, the impact of CYP2C19 polymorphism on the effectiveness of SSRI class drugs, namely citalopram, escitalopram, and sertraline, are explored. Nine relevant articles related to the topic have been studied in Japan, China, Turkey, Russia, Scandinavia, and Australia. The results concluded that CYP2C19 polymorphism can influence the metabolism of SSRIs (citalopram, escitalopram, and sertraline) due to its variability in enzyme activities, which includes both loss-of-function (*2, *3) and gain-of-function (*17) polymorphisms. Consequently, these genetic variations can lead to significant changes in drug efficacy and safety changes within individual patients. This review sheds light on the importance of considering genetic factors when prescribing SSRIs for MDD in the future treatment strategies.</dc:description>
	<dc:publisher xml:lang="en-US">Faculty of Medicine, Universitas Diponegoro</dc:publisher>
	<dc:date>2024-04-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/20338</dc:identifier>
	<dc:identifier>10.14710/jbtr.v10i1.20338</dc:identifier>
	<dc:source xml:lang="en-US">Journal of Biomedicine and Translational Research; Vol 10, No 1 (2024): April 2024; 40-47</dc:source>
	<dc:source>2503-2178</dc:source>
	<dc:source>10.14710/jbtr.v10i1</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/20338/10760</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2024 Journal of Biomedicine and Translational Research</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>